Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma
Alexander M Lesokhin1,2, Susan Bal3, Ashraf Z Badros4
1Memorial Sloan Kettering Cancer Center, New York, New York. lesokhia@mskcc.org.
Abstract:
Immune checkpoints and agonists modulate ongoing, antigen-specific immune responses. Therapeutic blockade of CTLA-4, PD-1, and PD-L1 has proven to be an effective treatment approach for a subset of patients with a variety of cancers of epithelial, mesenchymal, or hematologic origin. In multiple myeloma, a B-cell lymphoid malignancy of terminally differentiated plasma cells, PD-1 pathway blockade is ineffective as a single agent. The initial promise in combination approaches utilizing anti-PD-1 with the immunomodulatory drugs, lenalidomide or pomalidomide, was not confirmed in randomized trials. Here, we explore available data for and against manipulation of the PD-1 pathway and other immune checkpoints in myeloma and highlight several promising concepts and challenges that face ongoing development of immunotherapeutics for this disease.
Insights
Immune checkpoint inhibitors like PD-1 blockade are effective in many cancers but not as a single agent for multiple myeloma. Combination therapies also showed limited success, necessitating new strategies for this B-cell malignancy.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Immune checkpoints (e.g., CTLA-4, PD-1, PD-L1) regulate immune responses.
- Therapeutic blockade of these checkpoints is effective for various cancers.
- Multiple myeloma, a plasma cell malignancy, shows limited response to PD-1 pathway blockade alone.
Purpose of the Study:
- To review evidence supporting and opposing PD-1 pathway manipulation in multiple myeloma.
- To identify promising concepts and challenges in developing immune checkpoint-based therapies for myeloma.
Main Methods:
- Review of existing clinical trial data and scientific literature.
- Analysis of immune checkpoint inhibitor efficacy in multiple myeloma.
- Exploration of combination therapy outcomes.
Main Results:
- Single-agent PD-1 blockade is ineffective in multiple myeloma.
- Combination therapies (anti-PD-1 with lenalidomide/pomalidomide) did not meet expectations in randomized trials.
- The PD-1 pathway's role in myeloma requires further investigation.
Conclusions:
- Despite challenges, exploring PD-1 pathway manipulation and other immune checkpoints remains crucial for advancing multiple myeloma immunotherapy.
- Novel strategies are needed to overcome resistance and improve treatment outcomes for myeloma patients.
Related Concept Videos
01:29Neuromuscular Junction And Blockade
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
01:26PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
01:07Time-Domain Interpretation of PD Control
Consider the example of control of motor torque. Initially, a positive...
01:24Frequency-Domain Interpretation of PD Control
The proportional control gain, combined with the...
01:14Avoidance Learning and Learned Helplessness
Avoidance learning occurs when an organism learns that a specific behavior can prevent an unpleasant outcome. For example, a student who receives a bad grade may start studying harder to avoid future poor grades. This behavior persists even when the negative outcome is no longer present. Avoidance learning is powerful because it maintains behavior in the absence of the...